$590m to Moderna from HHS for mRNA ‘flu vax development
The funds aim to expedite late-stage development and licensing of the company's pre-pandemic mRNA vaccines.
The funds aim to expedite late-stage development and licensing of the company's pre-pandemic mRNA vaccines.